The Center for Skeletal Research (CSR), based in the Endocrine Unit at MGH, and funded by the National Institute of Arthritis and Musculoskeletal Diseases (NIAMS) is announcing a request for Pilot and Feasibility Research proposals
LETTER OF INTENT DUE MONDAY APRIL 5, 2021 5PM EST
Letter of intent should include
- a 250 word abstract
- a 150 word statement of eligibility
- an NIH style biosketch including all other support.
Please submit in a single PDF file to email@example.com
In the subject line include your last name and “P30P+F LOI” eg: SmithP30P+F LOI
THOSE INVITED TO APPLY FOR FUNDING WILL BE INFORMED BY WEDNESDAY, APRIL 7th, 2021
A THREE PAGE SCIENTIFIC PROPOSAL WILL BE REQUIRED BY MONDAY, MAY 3rd, 2021
Eligibility is based on the criteria listed below:
- Junior faculty proposing highly focused Skeletal Biology research projects with the goal of generating preliminary data sufficient to support an application for independent NIH research support. Applicants in this group must meet the NIH Early Investigator Criteria (New Investigators who have had less than 10 years of research or research training experience after the completion of their terminal research degree or medical residency, see http://grants.nih.gov/grants/new_investigators/index.htm) Awardees of K grants in their last 2 years of K funding may apply with committed effort but cannot receive salary from the P&F.
- Established researchers from outside the bone field proposing innovative studies relevant to Skeletal Biology.
- Established Skeletal Biology investigators proposing studies relevant to Skeletal Biology that represents a clear departure from their established line of investigation.
Investigators must invest at least 1 calendar month of effort. If salary requests do not reflect this effort, cost-sharing plans must be indicated. Applicants who are not U.S. citizens or permanent U.S. residents must have active visas permitting them to remain in the U.S. for the full period of the proposed research.
Please submit the following in a single PDF file to firstname.lastname@example.org
In the subject line include your last name and “P30P+F” eg: SmithP30P+F
- PHS form 398 pages 1,2,4 and 5 including a budget justification.
- Research plan, including Specific Aims on PHS 398 continuation page, not to exceed 3 pages conforming to standard NIH font and margin requirements. Page limitations exclude references.
- Biosketch in NIH PHS 398 format including other support with dollar amounts.
- A personal statement describing the candidate’s background and addressing eligibility criteria above (category 1, 2 or 3), current goals and how the P&F will impact these goals, not to exceed 500 words.
- IACUC/IRB approval must be received prior to funding.
|PI||TITLE OF PROJECT|
|Christian Jacome-Galarza||Title Cellular origins and functions of osteoclasts precursors in arthritis|
|Masao Kaneki||Targeting myostatin-activin type 2 receptor pathway prevents burn injury-induced bone loss|
|Jessica Lehoczky||ANCHORING LGR6 TO OSTEOGENESIS|
|Eva S. Liu, M.D.||Role of 1, 25 dihydroxyvitamin D in the development of enthesopathy in X-linked hypophosphatemia|
|Michael B. Albro, M.S., Ph.D.||Targeted Inhibition of Pathogenic TGF-beta Activity in Osteoarthritis|
|Diana L. Carlone, Ph.D.||Cfp1 Action in Chondrogenesis|
|LI Zeng, Ph.D.||The Role of T lymphocytes in Osteoarthritis Progression|
|Frank Ko, Ph.D.||The effects of caloric restriction on bone formation and mTOR signaling|
|Michaela Reagan, Ph.D.||Targeting sclerostin in multiple myeloma-induced bone disease|
|Keertik Fulzele, Ph.D.||Metabolic effect of bone secreted Wnt-signaling inhibitor sclerostin|
|Marc Wein, M.D., Ph.D.||Control of osteocyte biology by salt inducible kinases|
|(Year 2) Agnes Berendsen, Ph.D.||VEGF-dependent control of osteoblast/adipocyte differentiation|
|Jenna Galloway, Ph.D.||A zebrafish model of tendon-bone attachment injury and regeneration|
|Agnes Berendsen, Ph.D.||VEGF-dependent control of osteoblast/adipocyte differentiation|
|Melissa Putman, M.D.||Whole body vibration to prevent the musculoskeletal complications of immobility|